 Joseph Kay
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Defects, Congenital | 23 | 2024 | 834 | 1.840 |
Why?
| | Transposition of Great Vessels | 8 | 2024 | 36 | 1.360 |
Why?
| | Cardiac Catheterization | 10 | 2025 | 528 | 0.960 |
Why?
| | Tetralogy of Fallot | 9 | 2018 | 78 | 0.920 |
Why?
| | Fontan Procedure | 6 | 2024 | 180 | 0.890 |
Why?
| | Pulmonary Valve | 6 | 2025 | 98 | 0.680 |
Why?
| | Aortic Coarctation | 3 | 2023 | 83 | 0.630 |
Why?
| | Catheter Ablation | 8 | 2019 | 349 | 0.570 |
Why?
| | Stents | 6 | 2018 | 529 | 0.550 |
Why?
| | Atrial Fibrillation | 6 | 2022 | 390 | 0.550 |
Why?
| | Heart Valve Prosthesis Implantation | 5 | 2025 | 182 | 0.530 |
Why?
| | Tachycardia, Ventricular | 5 | 2019 | 175 | 0.510 |
Why?
| | Pacemaker, Artificial | 3 | 2020 | 119 | 0.510 |
Why?
| | Hypoplastic Left Heart Syndrome | 3 | 2024 | 121 | 0.500 |
Why?
| | Cardiology | 2 | 2020 | 278 | 0.490 |
Why?
| | Pulmonary Valve Insufficiency | 4 | 2025 | 43 | 0.450 |
Why?
| | Thromboembolism | 4 | 2024 | 119 | 0.400 |
Why?
| | Heart Valve Diseases | 3 | 2020 | 152 | 0.390 |
Why?
| | Heart Septal Defects, Atrial | 3 | 2013 | 54 | 0.390 |
Why?
| | Heart Failure | 5 | 2025 | 2234 | 0.380 |
Why?
| | Ultrasonography, Interventional | 3 | 2013 | 142 | 0.340 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2023 | 236 | 0.340 |
Why?
| | Arrhythmias, Cardiac | 5 | 2024 | 333 | 0.340 |
Why?
| | Coronary Angiography | 5 | 2024 | 312 | 0.340 |
Why?
| | Heart Ventricles | 4 | 2024 | 792 | 0.330 |
Why?
| | Arterial Switch Operation | 2 | 2022 | 9 | 0.320 |
Why?
| | Adult | 45 | 2025 | 37724 | 0.320 |
Why?
| | Sick Sinus Syndrome | 1 | 2009 | 2 | 0.310 |
Why?
| | Electrophysiologic Techniques, Cardiac | 7 | 2019 | 82 | 0.310 |
Why?
| | Treatment Outcome | 23 | 2025 | 10800 | 0.310 |
Why?
| | Bradycardia | 1 | 2009 | 55 | 0.300 |
Why?
| | Antiphospholipid Syndrome | 1 | 2009 | 38 | 0.290 |
Why?
| | Catheterization | 2 | 2010 | 179 | 0.290 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2025 | 69 | 0.290 |
Why?
| | Aneurysm, False | 1 | 2008 | 48 | 0.280 |
Why?
| | Follow-Up Studies | 14 | 2024 | 5125 | 0.280 |
Why?
| | Retrospective Studies | 25 | 2025 | 15639 | 0.260 |
Why?
| | Atrial Flutter | 3 | 2017 | 36 | 0.260 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2008 | 131 | 0.260 |
Why?
| | Male | 46 | 2025 | 67560 | 0.250 |
Why?
| | Humans | 65 | 2025 | 137294 | 0.250 |
Why?
| | Hemodynamics | 4 | 2025 | 1110 | 0.240 |
Why?
| | Female | 44 | 2025 | 73052 | 0.240 |
Why?
| | Hypertension | 3 | 2023 | 1285 | 0.240 |
Why?
| | Forecasting | 2 | 2017 | 387 | 0.230 |
Why?
| | Cardiac Surgical Procedures | 4 | 2018 | 530 | 0.230 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 3 | 2016 | 30 | 0.230 |
Why?
| | Cardiac Output | 1 | 2025 | 164 | 0.230 |
Why?
| | Cryosurgery | 2 | 2018 | 59 | 0.220 |
Why?
| | Vascular Fistula | 1 | 2024 | 23 | 0.220 |
Why?
| | Heart Rate | 3 | 2019 | 823 | 0.210 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2023 | 24 | 0.210 |
Why?
| | Risk Assessment | 5 | 2017 | 3439 | 0.210 |
Why?
| | Echocardiography, Transesophageal | 3 | 2010 | 101 | 0.200 |
Why?
| | Electrocardiography | 7 | 2017 | 630 | 0.200 |
Why?
| | Heart Transplantation | 3 | 2024 | 747 | 0.200 |
Why?
| | Young Adult | 18 | 2025 | 13163 | 0.200 |
Why?
| | Time Factors | 9 | 2025 | 6818 | 0.200 |
Why?
| | Prostheses and Implants | 1 | 2004 | 143 | 0.200 |
Why?
| | Heart Valve Prosthesis | 2 | 2025 | 116 | 0.190 |
Why?
| | Adolescent | 18 | 2025 | 21499 | 0.190 |
Why?
| | Ventricular Function, Left | 1 | 2025 | 540 | 0.190 |
Why?
| | Takayasu Arteritis | 1 | 2001 | 16 | 0.180 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1045 | 0.180 |
Why?
| | American Heart Association | 3 | 2017 | 306 | 0.180 |
Why?
| | Anticoagulants | 3 | 2022 | 662 | 0.180 |
Why?
| | Postoperative Complications | 4 | 2024 | 2658 | 0.180 |
Why?
| | Continuity of Patient Care | 3 | 2020 | 280 | 0.180 |
Why?
| | Middle Aged | 22 | 2025 | 33310 | 0.170 |
Why?
| | Heart Septal Defects, Ventricular | 2 | 2019 | 42 | 0.170 |
Why?
| | Data Collection | 2 | 2013 | 669 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2023 | 361 | 0.160 |
Why?
| | Cardiologists | 1 | 2020 | 45 | 0.160 |
Why?
| | Radiology, Interventional | 1 | 2020 | 33 | 0.160 |
Why?
| | Child Welfare | 1 | 2001 | 218 | 0.160 |
Why?
| | Prevalence | 8 | 2024 | 2715 | 0.150 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2013 | 389 | 0.150 |
Why?
| | Marfan Syndrome | 2 | 2019 | 41 | 0.150 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2018 | 43 | 0.150 |
Why?
| | Aortic Valve Insufficiency | 2 | 2015 | 47 | 0.140 |
Why?
| | Patient Education as Topic | 2 | 2013 | 762 | 0.140 |
Why?
| | Preoperative Care | 2 | 2018 | 358 | 0.140 |
Why?
| | Exercise | 2 | 2025 | 2045 | 0.140 |
Why?
| | Child | 15 | 2025 | 21999 | 0.140 |
Why?
| | Antihypertensive Agents | 1 | 2001 | 488 | 0.140 |
Why?
| | Tachycardia, Reciprocating | 1 | 2017 | 6 | 0.140 |
Why?
| | Coronary Artery Disease | 1 | 2024 | 703 | 0.140 |
Why?
| | Child, Preschool | 10 | 2024 | 11080 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 189 | 0.140 |
Why?
| | Aortic Valve Stenosis | 1 | 2020 | 229 | 0.140 |
Why?
| | Tachycardia, Supraventricular | 1 | 2017 | 43 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2023 | 785 | 0.130 |
Why?
| | Hepatic Veins | 2 | 2016 | 33 | 0.130 |
Why?
| | Aortic Valve | 2 | 2020 | 352 | 0.130 |
Why?
| | Pediatrics | 2 | 2001 | 1113 | 0.130 |
Why?
| | Survivors | 1 | 2020 | 488 | 0.130 |
Why?
| | Aorta | 2 | 2023 | 417 | 0.120 |
Why?
| | Tachycardia | 1 | 2016 | 58 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 871 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 844 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 482 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 313 | 0.120 |
Why?
| | Vectorcardiography | 1 | 2014 | 5 | 0.120 |
Why?
| | Risk Factors | 9 | 2025 | 10368 | 0.120 |
Why?
| | Age Factors | 6 | 2017 | 3297 | 0.120 |
Why?
| | Pulmonary Veins | 1 | 2016 | 99 | 0.110 |
Why?
| | Biomedical Research | 2 | 2013 | 693 | 0.110 |
Why?
| | Radiography, Interventional | 2 | 2013 | 114 | 0.110 |
Why?
| | Glutamate Carboxypeptidase II | 1 | 2013 | 5 | 0.110 |
Why?
| | Tricuspid Valve | 1 | 2014 | 30 | 0.110 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2013 | 11 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 552 | 0.110 |
Why?
| | Antigens, Surface | 1 | 2013 | 153 | 0.100 |
Why?
| | Eisenmenger Complex | 1 | 2013 | 11 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 627 | 0.100 |
Why?
| | Cardiac Care Facilities | 1 | 2013 | 13 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 4 | 2015 | 2679 | 0.100 |
Why?
| | Electrodes, Implanted | 1 | 2013 | 109 | 0.100 |
Why?
| | Heart Atria | 1 | 2014 | 136 | 0.100 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 201 | 0.100 |
Why?
| | Microbubbles | 1 | 2013 | 49 | 0.100 |
Why?
| | Portal Vein | 1 | 2014 | 119 | 0.100 |
Why?
| | Ventricular Function, Right | 2 | 2025 | 283 | 0.100 |
Why?
| | Diastole | 1 | 2013 | 150 | 0.100 |
Why?
| | Hypoxia | 1 | 2020 | 1111 | 0.100 |
Why?
| | Sodium Chloride | 1 | 2013 | 142 | 0.100 |
Why?
| | Prosthesis Design | 3 | 2018 | 329 | 0.100 |
Why?
| | Predictive Value of Tests | 6 | 2014 | 2032 | 0.090 |
Why?
| | Severity of Illness Index | 4 | 2019 | 2836 | 0.090 |
Why?
| | Aortic Diseases | 1 | 2012 | 117 | 0.090 |
Why?
| | Therapy, Computer-Assisted | 1 | 2011 | 62 | 0.090 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 107 | 0.090 |
Why?
| | Angioplasty, Balloon | 1 | 2011 | 93 | 0.090 |
Why?
| | Exercise Test | 3 | 2023 | 625 | 0.090 |
Why?
| | Heart Diseases | 3 | 2013 | 359 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1077 | 0.080 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 77 | 0.080 |
Why?
| | Imaging, Three-Dimensional | 2 | 2011 | 577 | 0.080 |
Why?
| | Echocardiography | 1 | 2013 | 659 | 0.080 |
Why?
| | Internship and Residency | 1 | 2020 | 1137 | 0.080 |
Why?
| | Patient Participation | 1 | 2013 | 417 | 0.080 |
Why?
| | Cell Movement | 1 | 2013 | 969 | 0.080 |
Why?
| | Prospective Studies | 7 | 2018 | 7595 | 0.080 |
Why?
| | Infant | 6 | 2024 | 9451 | 0.080 |
Why?
| | Aged | 8 | 2025 | 23851 | 0.080 |
Why?
| | Anti-Arrhythmia Agents | 2 | 2019 | 114 | 0.070 |
Why?
| | Equipment Failure | 1 | 2009 | 108 | 0.070 |
Why?
| | Clinical Trials as Topic | 3 | 2003 | 1045 | 0.070 |
Why?
| | Chest Pain | 1 | 2009 | 92 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2011 | 411 | 0.070 |
Why?
| | Cost of Illness | 2 | 2024 | 303 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1399 | 0.070 |
Why?
| | Colorado | 3 | 2025 | 4527 | 0.070 |
Why?
| | Diagnosis, Differential | 2 | 2001 | 1484 | 0.070 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 308 | 0.070 |
Why?
| | Fosinopril | 1 | 2006 | 1 | 0.070 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5436 | 0.060 |
Why?
| | Oxygen Consumption | 2 | 2025 | 696 | 0.060 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 210 | 0.060 |
Why?
| | Ventricular Pressure | 1 | 2025 | 48 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1084 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 907 | 0.060 |
Why?
| | United States | 6 | 2018 | 14742 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2013 | 1327 | 0.060 |
Why?
| | Incidence | 2 | 2024 | 2808 | 0.050 |
Why?
| | Altitude | 1 | 2008 | 485 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 740 | 0.050 |
Why?
| | North America | 1 | 2024 | 313 | 0.050 |
Why?
| | Patient Selection | 2 | 2010 | 692 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2025 | 279 | 0.050 |
Why?
| | International Normalized Ratio | 1 | 2022 | 47 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2019 | 7607 | 0.050 |
Why?
| | Vitamin K | 1 | 2022 | 44 | 0.050 |
Why?
| | Digoxin | 1 | 2001 | 30 | 0.050 |
Why?
| | Carotid Artery Diseases | 1 | 2002 | 66 | 0.050 |
Why?
| | Pulmonary Atresia | 2 | 2012 | 21 | 0.050 |
Why?
| | Diuretics | 1 | 2001 | 74 | 0.050 |
Why?
| | Prognosis | 2 | 2024 | 4026 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2001 | 77 | 0.040 |
Why?
| | Ethics, Medical | 1 | 2001 | 84 | 0.040 |
Why?
| | Arteries | 1 | 2022 | 269 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5726 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1521 | 0.040 |
Why?
| | Reference Values | 1 | 2001 | 818 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 272 | 0.040 |
Why?
| | Social Support | 1 | 2024 | 619 | 0.040 |
Why?
| | Gonadal Dysgenesis | 1 | 2019 | 7 | 0.040 |
Why?
| | Philadelphia | 1 | 2019 | 49 | 0.040 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 323 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2007 | 982 | 0.040 |
Why?
| | Coronary Disease | 1 | 2002 | 385 | 0.040 |
Why?
| | Prader-Willi Syndrome | 1 | 2019 | 27 | 0.040 |
Why?
| | Ultrasonography | 2 | 2014 | 752 | 0.040 |
Why?
| | DiGeorge Syndrome | 1 | 2019 | 32 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 1946 | 0.040 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2019 | 62 | 0.040 |
Why?
| | Fragile X Syndrome | 1 | 2019 | 77 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2661 | 0.040 |
Why?
| | Quality of Life | 2 | 2024 | 2885 | 0.040 |
Why?
| | Mood Disorders | 1 | 2019 | 129 | 0.040 |
Why?
| | Palliative Care | 1 | 2024 | 747 | 0.040 |
Why?
| | Quebec | 1 | 2017 | 11 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 723 | 0.030 |
Why?
| | Perioperative Period | 1 | 2017 | 56 | 0.030 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2017 | 63 | 0.030 |
Why?
| | Heart Conduction System | 1 | 2017 | 101 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 680 | 0.030 |
Why?
| | Reoperation | 1 | 2019 | 583 | 0.030 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2020 | 292 | 0.030 |
Why?
| | Blood Pressure | 1 | 2023 | 1776 | 0.030 |
Why?
| | Action Potentials | 1 | 2019 | 495 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1059 | 0.030 |
Why?
| | Anxiety Disorders | 1 | 2019 | 374 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1464 | 0.030 |
Why?
| | Electric Stimulation | 1 | 2016 | 264 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 131 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 548 | 0.030 |
Why?
| | Angiography | 1 | 2015 | 207 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2008 | 6054 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2016 | 240 | 0.030 |
Why?
| | Liver Diseases | 1 | 2017 | 311 | 0.030 |
Why?
| | Recovery of Function | 1 | 2018 | 657 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1067 | 0.030 |
Why?
| | Health Surveys | 1 | 2016 | 517 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2017 | 406 | 0.030 |
Why?
| | Prostatectomy | 1 | 2013 | 104 | 0.030 |
Why?
| | Curriculum | 1 | 2020 | 983 | 0.030 |
Why?
| | Phlebography | 1 | 2013 | 38 | 0.030 |
Why?
| | Sinus of Valsalva | 1 | 2012 | 10 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2012 | 61 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 306 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 324 | 0.020 |
Why?
| | Down Syndrome | 1 | 2019 | 491 | 0.020 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 98 | 0.020 |
Why?
| | Clinical Competence | 1 | 2020 | 1100 | 0.020 |
Why?
| | Fluoroscopy | 1 | 2013 | 157 | 0.020 |
Why?
| | Prosthesis Implantation | 1 | 2013 | 154 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2013 | 109 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2013 | 234 | 0.020 |
Why?
| | RNA Interference | 1 | 2013 | 467 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2071 | 0.020 |
Why?
| | Cineangiography | 1 | 2011 | 9 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 976 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 892 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 658 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1226 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 242 | 0.020 |
Why?
| | Septal Occluder Device | 1 | 2010 | 30 | 0.020 |
Why?
| | Substance-Related Disorders | 1 | 2019 | 1073 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 949 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1374 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1734 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 5 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 8 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 23 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 462 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 152 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 846 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1700 | 0.020 |
Why?
| | Treatment Failure | 1 | 2008 | 354 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1274 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 430 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1774 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 1034 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3414 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3283 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2850 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2007 | 273 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 752 | 0.010 |
Why?
| | Length of Stay | 1 | 2008 | 1218 | 0.010 |
Why?
| | Animals | 1 | 2025 | 36862 | 0.010 |
Why?
| | ortho-Aminobenzoates | 1 | 2002 | 10 | 0.010 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 24 | 0.010 |
Why?
| | Coronary Restenosis | 1 | 2002 | 21 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2052 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3568 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 1985 | 0.010 |
Why?
| | Paclitaxel | 1 | 2002 | 227 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5769 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 362 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6743 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2002 | 461 | 0.010 |
Why?
| | Body Mass Index | 1 | 2006 | 2373 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2002 | 2135 | 0.010 |
Why?
|
|
Kay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|